Lineage Cell Therapeutics Inc (LCTX)

[DeepDive]

"Why is that dreamy OpRegan stuff that only we scientists and other such disreputables smile care about not included in the AgeX spinoff?"

Because OpRegen is the nearest catalyst and has incredible upside, and Biotime management wisely does not want to dilute its holding in this very promising platform product.

BTX holding in AgeX will be diluted to below 50% at which the business can appear on BTX's balance sheet as an asset (market to market) rather than consolidated reporting that ignores market value.

OpRegen will also generate cash flow for BTX that can be used to keep it's holding in promising subs significant and used to further allocate into promising high margin activities.